Allarity Therapeutics A/S announced that it has enrolled the first patient in its European Phase II clinical trial of Ixempra (ixabepilone) for the treatment of metastatic breast cancer.
Allarity Therapeutics, Inc. which is developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, announced initial results from its European Phase II clinical trial evaluating the efficacy of Ixempra in metastatic breast cancer (mBC) patients selected with the DRP-Ixempra companion diagnostic (CDx) candidate
Oncology Venture A/S announced that the company has obtained an exclusive option to in-license the European rights to Ixempra (ixabepilone)...